x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

science life sciences

All Episodes

00:10:27

May 13, 2026 | BeOne's Beqalzi Wins FDA Approval,...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/14

FDA approves Beqalzi (sonrotoclax) for mantle cell lymphoma — the first new BCL-2 inhibitor in a decade, directly challenging AbbVie's Venclexta franchise. Takeda slashes 4,500 jobs in a $1.26B restructuring; Lilly and Novo duel with new obesity maintenance data on the same day.Visit us a www.thepharmcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, BeOne, Beqalzi, sonrotoclax, BCL-2 inhibitor, mantle cell lymphoma,

en-us

00:10:37

May 12, 2026 | FDA Commissioner Makary Resigns;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/13

FDA Commissioner Makary resigns; Kyle Diamantas steps in as acting chief amid regulatory upheaval. BMS and Hengrui ink $15.2B alliance across 13 programs in oncology, hematology, and immunology. Lilly's Foundayo maintains 82% of weight loss vs. Wegovy switch in ATTAIN-MAINTAIN Phase 3 data.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Marty Makary, Kyle Diamantas, Bristol Myers Squibb, BMS,

en-us

00:11:07

May 11, 2026 | CSL Flags $5B Vifor Impairment as...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/12

CSL's $5B write-down from the Vifor Pharma acquisition sends shares to a nine-year low — the largest single-day drop on record. Inhibrx's INBRX-106 posts 44% ORR vs Keytruda's 21% in head and neck cancer. PlusRezdiffra clears $311M in Q1, Fractyl's GLP-1 gene therapy gets European clinical trial greenlight, and Daiichi Sankyo targets global top-5 oncology by 2035.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare,

en-us

00:13:57

May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/11

FDA approves Vyvgart for all adult gMG serotypes two daysbefore PDUFA — argenx locks in broadest MG label with no FcRn rival in seronegative disease. Plus Merck's $6.7B Terns completion, Avalo's Phase 2 HS win, and Gilead's billion-dollar PrEP forecast.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Vyvgart,efgartigimod, argenx, myasthenia gravis, seronegative gMG, ADAPT SERON, Merck,Terns

en-us

00:10:24

May 08, 2026 | Trump Plans to Fire FDA Commissioner...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/09

FDA leadership in crisis — multiple outlets report Trump will fire Commissioner Makary after 14 turbulent months. Leqembi SC review extended three months to August 24. Bayer acquires Perfuse for $2.45B; Daiichi Sankyo takes $610M ADC manufacturing hit; Gilead targets $1B in Yeztugo sales.Visit us at www.thepharmcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Marty Makary, Trump, Leqembi, lecanemab, Eisai, Biogen,

en-us

00:10:27

May 07, 2026 | Angelini's $4.1B Catalyst Buyout;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/08

Angelini Pharma pays $4.1B cash for Catalyst Pharmaceuticals — the fourth biotech buyout this month. Atara surges 40%+ on FDA path to resubmit tab-cel BLA. Roche acquires PathAI in $1B+ AI diagnostics deal. Duchenne takes two hits as Entrada data disappoint and Sarepta slides.Visit us at www. thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Angelini Pharma,Catalyst Pharmaceuticals, Firdapse, amifampridine,

en-us

00:10:20

May 06, 2026 | Bayer Acquires Perfuse for $2.45B in...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/07

Bayer bets up to $2.45B on glaucoma drug maker PerfuseTherapeutics — its biggest pharma deal in years. Novo's oral Wegovy hits $355M in Q1, the strongest GLP-1 launch by volume in the US. Plus UCB's $2.2B Candid deal, GSK's $1B SiranBio siRNA licensing, Lilly's $4.5B manufacturing pledge, and Sanofi walks away from the FDA's CNPV program.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The

en-us

00:10:25

May 05, 2026 | Cytokinetics Cracks Non-Obstructive...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/05

Myqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3 siRNA for up to $1B, and the Supreme Court keeps mifepristone in play.Visit us at www.thepharamcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Cytokinetics,Myqorzo, aficamten, hypertrophic

en-us

00:09:31

May 04, 2026 | SCOTUS Restores Mifepristone Mail...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/05

Supreme Court grants emergency stay restoring mifepristone access — and the ruling's implications hit every drugmaker's risk model. Plus: Arvinas/Pfizer's vepdegestrant becomes the first PROTAC approved by the FDA, UCB acquires Candid Therapeutics for $2.2B in autoimmune bispecifics, and Cytokinetics' pivotal HCM readout lands tomorrow.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:13:05

May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/04

UCB drops $2B upfront for Candid Therapeutics' autoimmune T-cell engager cizutamig — their second billion-dollar deal in three weeks. FDA proposes withdrawing Amgen's Tavneos over data manipulation allegations. Pfizer/Arvinas' Veppanubecomes the first approved PROTAC degraderVisit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, UCB, Candid vTherapeutics, cizutamig, autoimmune, T-cell

en-us

00:10:27

May 01, 2026 | FDA Approves First PROTAC Drug...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/04

FDA clears Veppanu, the first protein degrader to reachmarket — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgency drives a mega year. Plus: Truqap wins 7-1 ODAC vote in prostate cancer, Auvelity expands into Alzheimer's agitation, and Summit's ivonescimab stumbles before ASCO.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Veppanu,vepdegestrant,

en-us

00:10:07

Apr 28, 2026 | Erasca Crashes 48% on Patient Death;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/29

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli

en-us

00:10:36

Apr 27, 2026 | Sun Pharma just wrote an...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/28

Sun Pharma just wrote an eleven-point-seven-five billiondollar check to acquire Organon — the largest outbound pharma acquisition in Indian history, according to Reuters. And Intellia's in vivo CRISPR therapyjust delivered the first Phase 3 win for gene editing inside the body. Big Monday. Let's get into it.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Eli Lilly, Lilly,

en-us

00:10:26

Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/25

Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly,

en-us

00:09:26

Apr 23, 2026 | Regeneron's Otarmeni Approved as First...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/24

FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, Otarmeni, gene therapy, hearing loss, FDA

en-us

00:10:04

Apr 21, 2026 | Merck Welireg Fails First-Line Kidney...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/22

Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefinitely delays GLP-1 weight loss drug coverage pilot. Plus AstraZeneca IgAN data, Roche MOGAD results, Arrowhead upgrade.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Welireg, belzutifan, kidney cancer, renal cell carcinoma, Keytruda,

en-us

00:10:26

Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/21

Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March 2025. Plus Gilead-Arcus TIGIT Phase 3 failure, Nektar's 20%+ alopecia surge, Trump's psychedelic executive order, AACR KRAS data from Revolution Medicines, and Novo Nordisk sickle cell Phase 3 results.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The

en-us

00:13:27

Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/21

Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's $1.2B Neurona acquisition for epilepsy cell therapy, Spyre'sbest-in-class UC data, Lilly Foundayo's launch metrics, and what to watch as AACR and Q1 earnings collide this week.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:09:10

Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/17

Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismisses anti-amyloid Alzheimer's drugs, Daiichi Sankyo divests $1.5B consumer health unit, and Kailera's $533M obesity IPO pricesahead of tomorrow's trading.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,orforglipron, Eli Lilly,

en-us

00:09:41

Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/16

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines,

en-us

121 results

Similar Podcasts

Mothman Podcast

Mothman Podcast

Autobiography of an Electron

Charles R. Gibson

This is a Science Show

Dustin Driver

Get Into Gate: A Stargate Podcast

Get Into Geek

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group